Arthritis Foundation Logo
Español ES
Your Local Area
Sign In
Popular Search
arthritis gout home ja
Suggested Content
Article
Rx for Access
Online resource that helps patients better understand health coverage options, choose the right coverage, manage the denial process and reduce health care costs.
Article
Do I Have Arthritis?
Think you may have arthritis? Learn about the four most common warning signs.
Article
Gout
Gout is an inflammatory type of arthritis that can come and go.
Arthritis Foundation Logo
  • About Arthritis
    Common Topics
    woman holding her wrist What Is Arthritis?

    Arthritis is not one disease. Learn about the different types of arthritis, how they differ and why it’s important.

    microbes Inflammation and the Immune System

    Body-wide inflammation is at the root of most chronic diseases — and you may have more control over it than you think.

    Patient talking with nurse Newly Diagnosed With Arthritis

    A new arthritis diagnosis can be overwhelming. These tips can help.

    • Understanding Arthritis
    • Arthritis Types
    • More About Arthritis
    • Where it Hurts
    • Related Conditions
  • Treatments
    Common Topics
    Woman holding shoulder Webinar: Touch Therapies for Pain Management

    Learn the evidence behind popular touch therapies for arthritis, including what to try and what to avoid, for how long and when.

    Managing Arthritis Care Costs

    Learn the basics about health care costs and financial tools available to you.

    Man with head in hands on bed Webinar: Arthritis Fatigue Causes and Solutions

    Learn the various causes of arthritis-related fatigue and strategies to combat weariness.

    • Treatment Plan
    • Drug Guide
    • Joint Surgery
    • Complementary Therapies
    • Insurance Management
  • Healthy Living
    Common Topics
    Woman with upset stomach Microbiome, Gut Health & Arthritis

    Microbiome, microbes, microorganisms – these terms may be confusing, but the types of bacteria living in and on our bodies can impact arthritis. Learn what helps or harms the microbiome and the health of your gut and discover dietary changes that can make a difference. This episode was originally released on January 19, 2021.

    man exercising Stairs Workout Demo

    Strengthen your leg muscles and improve your stability to make going up and down stairs safer and easier.

    woman consoling another Arthritis and Mental Health

    Learn about the connection between arthritis, depression and anxiety and how these conditions can make your arthritis worse.

    • Ease of Use Products
    • Managing Pain
    • Recipes & Nutrition
    • Physical Activity
    • Emotional Well-being
    • Daily Living
    • Family & Relationships
  • Juvenile Arthritis
    Common Topics
    2023 JA Family Summit

    Learn about the National Juvenile Arthritis Conference, a place for families to connect, share and learn.

    JA Camps

    The Arthritis Foundation’s JA camp programs give kids with arthritis and related childhood rheumatic diseases the chance to make lasting memories.

    Juvenile Arthritis Volunteer

    • About Juvenile Arthritis
    • Treatment
    • Managing Pain
    • Medical Decisions
    • Nutrition
    • Emotional Well-being
  • Professionals
    Common Topics
    Transforming Clinical Interactions

    The Live Yes! Arthritis community connects patients with others online and in-person for support and education, and encourages patients to play an active role in their health care.

    Partners 4 Patients with Arthritis

    The Arthritis Foundation recently launched an initiative to build stronger relationships and increase recognition of our most engaged practices.

    Fellowships

    See how we're aiming to address the growing shortage of arthritis specialists, especially in under-served parts of the country.

    • Better Living Toolkits
    • Our Issue Briefs
  • Science
    Common Topics
    OACS Forum Series

    The Osteoarthritis Clinical Studies Forum Series features OA thought leaders from across the globe discussing the future of how the disease can be treated to improve patient outcomes.

    man bandaging boy's knee Conquering Childhood Arthritis

    The Arthritis Foundation is mobilizing patients and their families to engage in studies comparing the effectiveness of treatments for juvenile arthritis and funding research for more options.

    Focus

    • Awards
    • Funding Opportunities
    • OACS Forum Series
    • Osteoarthritis Focus
    • Participate in Clinical Trials
    • Partnerships
    • Publications
  • Get Involved
    Common Topics
    Capital hill Action Center

    Take action today - use the resources here to learn who your elected officials are, what opportunities we have to advocate from the comfort of your own home, federal and state legislation, and more!

    LiveYes! Insights thumbnail Live Yes! INSIGHTS

    Share your experience in a 10-minute assessment to be among those changing the future of arthritis.

    woman listening to podcast Live Yes! Podcast

    You may have arthritis, but it doesn't have you. The Arthritis Foundation’s one-of-a-kind podcast. Hosted by patients, for patients.

    • Advocacy
    • Ways to Give
    • Fundraising
    • Volunteer
    • Partnership
    • Live Yes! Arthritis Community
Donate
Back

ACR 2020 Highlights: Dr. Anthony Fauci, Gout Guidelines, Osteoarthritis & Promoting Physical Activity

D ay three of the American College of Rheumatology’s annual meeting Saturday continued with sessions on biologics, osteoarthritis treatments, osteoporosis and more, a highlight was a l ecture on COVID-19 by Anthony Fauci , MD, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH ) , and a top advisor on COVID-19 .



Dr. Anthony Fauci on COVID-19 Background and Current Status
Dr. Fauci outlined the background and addressed the public health and scientific challenges of SARS-CoV-2, the novel coronavirus that causes COVID-19 , and the pandemic in the U.S and around the world. Here are some highlights from his pre-recorded lecture:

“We have had experience with coronaviruses now for decades and decades,” said Dr. Fauci . “Here we are now with a global pandemic of historic proportions the likes of which we have not seen in the last 102 years, since the now iconic pandemic outbreak of 1918 . ”

Globally, there are currently 48.1 million cases of COVID-19 and the virus accounts for over 1.2 million deaths.

“In the United States, we have been hit the hardest of any other country , with close to 10 million cases and over 230,000 deaths,” said Dr. Fauci . On Nov. 4 the U.S. hit a new high with 100,000 cases in a single day.

After much of Europe shut down, cases dropped and returned to a relatively low baseline. After the U.S. shut down, cases dropped, but never returned to a low baseline. Cases in the U.S. spiked after reopening, dropped again and now are steadily climbing. European cases have steadily climbed since reopening. Dr. Fauci pointed to significant differences in the degree to which the U.S. shut down compared to Europe.
“The fundamentals to preventing the acquisition and transmission of SARS-CoV-2 are five-fold : Universal wearing of masks ; m aintain physical distance of at least 6 feet ; a void crowds ; o utdoors is better than indoors ; f requent handwashing ,” said Dr. Fauci .

“If those five public health measures were adhered to universally and consistently over the country, it is clear from our previous experience with other nations and even regions in our own country that we would not have the degree of surging of cases that we are currently seeing,” said Dr. Fauci .

Dr. Fauci expects a vaccine to be available within months. “ The United States government has made major investments in the development of and facilitation of testing six [vaccine] candidates among the 11 [vaccine] candidates that are being tested worldwide,” he said. Five are in phase 3 trial , including two trials that are well advanced . He is “ cautiously optimistic that we will have a safe and effective vaccine by the end of this calendar year that we may be able to deploy early on in individuals with a high risk level, ” he said, “ That we will be able to give doses of vaccines beginning in 2021 and into the first few months of 2021.” — BRYAN VARGO

Biologics Then and Now
Gerd Burmester , MD, a professor of medicine in the Department of Rheumatology and Clinical Immunology at the Charité University Hospital in Berlin, discussed the evolution of biologics, beginning with the development of diphtheria antitoxin more than a century ago. This antibody therapy opened the door for the monoclonal antibodies used to treat rheumatoid arthritis (RA) and other autoimmune diseases today.

Dr. Burmester also explained the stories behind individual biologics. The earliest, like infliximab, use a combination of mouse and human proteins. Later drugs, such as adalimumab ( Humira ), are fully human. Arthritis drug targets are changing, too, from tumor necrosis factor (TNF) to interleukin -6 (IL-6 ) and IL-17. Some, including the IL-6 inhibitor sarilumab ( Kevzara ) are being tested for use in COVID -19 patients. A staunch advocate of tried-and-true biologics, he thinks they should be used before newer oral drugs like janus kinase inhibitors.

Although Dr. Burmester sees great progress in treating autoimmune disease with biologics, he is surprised that biosimilars haven’t made more inroads in the U.S. Biosimilars are FDA-approved drugs that are similar to already-approved biologics. They are widely used throughout Europe, where they have lowered treatment costs. As biosimilars gain even greater acceptance, costs are expected to come down even more.

So far, 14 biologics have been approved in the U.S. for inflammatory disease, but only three biosimilars are available for doctors to prescribe. The rest tied up in court s with pharmaceutical company patent challenges and legal settlements . Those biosimilars that are on the market in the U.S. have had an unexpectedly lukewarm reception from both providers and patients , he said . Dr. Burmester stressed that wider acceptance of biosimilars could lower drug costs and help more patients receive treatment. — LINDA RATH

Men Need Osteoporosis Screening
While screening and treatment of osteoporosis in women as they age is common and widely accepted, it’s a harder battle for men — even after they’ve experienced a bone fracture due to osteoporosis, said rheumatologist Jeffrey Curtis, MD, professor of medicine at the University of Alabama in Birmingham. Approximately a quarter of patients who experience these fractures are men, and evidence suggests they experience worse outcomes. Fractures also can contribute to worsening comorbid conditions.

Dr. Curtis and colleagues studied men age 65 and older who had a “fragility fracture.” Of the 9,876 patients, fewer than 6% had been tested for bone mineral density in the two years before the fracture, although 63% had a history of musculoskeletal pan and 48% had used opioids (which increases the risk) in the year prior. About 93% had no osteoporosis diagnosis or treatment before the fracture, 2.8% w e re diagnosed but not treated, 2.3% were treated but not diagnosed, and only 2.1% were diagnosed and treated.
“Men are being largely ignored for osteoporosis in the U.S .,” — Dr. Jeffrey Curtis .

“There is a high level of underdiagnosis and undertreatment of osteoporosis, even in the most at-risk groups of men with comorbid conditions associated with falls.”

A significant barrier is that policies and guidelines for screening for women don’t exist for men, and insurance companies don’t cover screening for men as they do for women – and may not reimburse the high costs of DXA scans (used to measure bone mineral density).

“Clinicians aren’t recognizing them and screening them appropriately. They’re hardly being treated even if they break bones,” Dr. Curtis said. “Because osteoporosis is silent and people generally don’t have symptoms in the absence of a fracture, patients aren’t coming into doctors’ offices asking to be tested.

“Even if they break bones, they may not know enough to ask how to prevent the next fracture,” he adds. “From the patient’s perspective, they may feel like the orthopedic surgeon did a great job repairing the broken bone, but nobody’s mentioning that, ‘Hey, there are medications that might help you avoid a future fracture.’”— JILL TYRER

Methotrexate for Osteoarthritis
Inflammation plays a critical role in osteoarthritis (OA) symptoms, but there aren’t any medications that specifically target OA-related inflammation. W hile guidelines don’t recommend the use of methotrexate (a drug commonly used to treat inflammatory forms of arthritis) for OA, there seems to be some evidence for its use, said Biswadip Ghosh, MD, associate professor o f rheumatology at the Institute of Post-Graduate Medical Education and Research in Kolkata, India.

To find out if methotrexate would relieve knee OA, he and his colleagues identified patients with knee OA and tested them to see if they had elevated CRP or ESR, markers of inflammation. (They also screened the patients to make sure they did not have inflammatory forms of arthritis. )

Of the patients who completed the study, 59 who had only local inflammation (no elevated CRP or ESR) received glucosamine as placebo , and 78 who had elevated markers of inflammation received methotrexate. At the end of three months, the methotrexate group showed statistically significant improvements not only in markers of inflammation but also in symptoms, including pain, stiffness and function, while the placebo group showed no significant improvement.

Dr. Ghosh concluded that methotrexate may be a treatment option for knee OA patients with inflammation, especially those who have not gotten adequate response from othe r anti-inflammatory therapies.

Do Steroid Shots Worsen OA?
A study last year that received a lot of attention found that corticosteroid (steroid) injections into joints can hasten joint damage by three-fold, raising alarms among doctors as well as patients. But while the authors accounted for a number of factors associated with worsening osteoarthritis (OA), one limitation of the study was that they did not compare steroid injections with a different type of joint injection – hyaluronic acid, or viscosupplementation – which is not associated with cartilage loss, said Justin Bucci, MD, an assistant professor of medicine at Boston University.

To determine whether corticosteroid injections are associated with increased knee OA progression, he and his colleagues looked at data from two studies of knee OA patients who had received steroid or hyaluronic acid injections. Comparing X-rays from before the first reported injection and from the time of knee replacement, they looked at deterioration rates in 647 knees receiving steroid injection and 145 receiving hyaluronic acid. Results showed similar rates of OA progression between the two groups.

Dr. Bucci concludes that the increased OA damage in the previous study was not from the corticosteroid injections but from more severe OA in those receiving injections of either kind.

While more research is needed to confirm the results and get more information about the different injections, he said, “I think we can provide some reassurance to patients and clinicians treating OA that corticosteroid injections are not causing the OA to get worse. Patients with moderate to severe OA that is not responding to conservative measures should still be offered cortisone injections.”— JILL TYRER

Promoting Physical Activity and its Benefits
Patricia Katz, PhD, professor of medicine and health policy at University of California San Francisco, shared her insights and 25 years of rheumatology research experience on the statistically significant evidence on the effects of physical activity on arthritis.

“The good news is we know exercise is recognized as safe and recommended for people with rheumatic and musculoskeletal diseases for quite some time,” says Katz. She cited a landmark study from 1989 by Marian Minor, PhD, that showed aerobic exercise reduced the number of tender joints and significantly improved functioning in people with arthritis, thus establishing exercise as both safe and helpful for arthritis patients . (Minor received the Arthritis Foundation’s Humanitarian of the Year award in 2000 . )

In a more recent study on high intensity interval training for patients with rheumatoid arthritis (RA), “They reported some pretty impressive results, with significant decreases in disease activity and swollen joints and they also reported improvements in physical function,” said Katz.

She detailed the impact that physical activity can have on symptoms from reducing pain and fatigue to improving depression symptoms and cognitive function. She also discussed potential barriers to physical activity for people with rheumatic conditions , emphasizing a lack of education.

“The most important reason people with rheumatic diseases are not exercising is they’re not getting the message that physical activity is a good thing for them, that it’s beneficial for their disease,” said Katz. “They’re not getting that message from their physicians or other health care providers.” — BRYAN D. VARGO

Tapering Methotrexate in Remission
Patients with chronic conditions get tired of having to take a lot of medications for a long time, not only for the side effects and hassle, but also for the expense. Medication burden can lead some to stop taking them as prescribed, which can put their health at risk.

Although guidelines for managing RA recommend tapering medications if possible, it isn’t clear how to go about that. So, in a recent study, rheumatologist Jeffrey Curtis, MD, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, took a look at RA patients who were in remission while taking the biologic medication etanercept and methotrexate to find out if they could safely reduce or eliminate one or the other drug.

People were determined to be in remission if both the y and their physicians agreed that their disease was well controlled for at least six months – that they had few swollen or tender joints, that they were doing well overall, and that their C-reactive protein (CRP, a marker of inflammation) levels were low. The researchers randomized 253 of these patients to receive either etanercept alone, methotrexate alone or to continue the combination. Ninety percent completed the study.

While similar proportions of the participants on etanercept alone and on combination therapy maintained remission – 49.5% and 52.9%, respectively – those on etanercept did not fare as well, with only 28.7% maintaining remission. Furthermore, those who failed remission on methotrexate did so sooner, about three to six months, than those on etanercept alone, about six months. Those who received “rescue therapy” were able to achieve remission again by the end of the year-long study.

“The implication here is that probably if you’re doing that well on both treatments, you can continue etanercept, stop methotrexate, and the majority of those people are going to do just as well,” Dr. Curtis said. “As a clinician, the risk to try this is quite low because the likelihood that you can regain where you were before is quite good.”— JILL TYRER

More Evidence for Gout Guidelines
Gout is a painful form of inflammatory arthritis affecting more than 8 million Americans, and it’s a condition that doctors in different specialties treat – but not all in the same ways. Gout occurs when uric acid levels build up in the blood, which can form needle-like crystals in joints – often a big toe – leading to acute pain and swelling. Patients often end up in the emergency room with a gout flare, and then to their primary care doctor rather than to a rheumatologist – and their treatment guidelines differ.

The ACR (which updated its treatment guideline earlier this year) recommends long-term treatment with a urate-lowering drug, such as allopurinol, and treating to target , which means adjusting medication levels until the patient reaches a target level of uric acid in the blood. But other medical professional organizations, such as the American College of Physicians, disagree with the treat-to-target approach or that urate-lowering drugs should be used long-term, citing insufficient evidence.

Robert Terkeltaub , MD, professor of medicine at the University of California, San Diego, chief of rheumatology at the VA Medical Center in San Diego and a leading gout expert, sought to bring more evidence to the table in a session Saturday. Citing several studies published in recent years, he presented evidence that urate-lowering therapy reduces gout flares and inflammation in the joint; that allopurinol and colchicine (another common gout medication) reduces urate levels as well as flares (compared to standard treatment from primary care); and that treat to target improves crystal deposits and limits joint erosion.

Questions remain about how to treat gout in patients with comorbid conditions, such as cardiovascular or kidney disease. But evidence shows that ACR’s guidelines on urate-lowering therapy are sound and newer trial data support them for “clinically meaningful gout outcomes , ” he said. — JILL TYRER
Get Involved
  • Live Yes! Arthritis Community
  • Live Yes! Connect Groups
  • Live Yes! Online Community
  • Local Office
  • Fundraising
  • Webinars
  • Volunteer Portal
  • Store
About
  • About Us
  • Annual Report
  • Careers
  • Code Of Ethics
  • Financials
  • News and Stories
  • Privacy Notice
  • Terms of Use
  • Español
Join Us
  • Jingle Bell Run
  • JA Camps
  • Pathways Conference 2023
  • Walk to Cure Arthritis
  • Fundraise Your Way
  • JA Family Summit
Home Office
  • 1355 Peachtree St NE Suite 600
  • Atlanta, GA 30309
  • Helpline: 1.800.283.7800
  • Contact Us
Mountain View, CA
49° Arthritis Index At Risk
See More Details
Arthritis Foundation is a qualified 501(c)(3) EIN 58-1341679
I Want to Contribute
I Need Help
  • Donate

    Donate

    Every gift to the Arthritis Foundation will help people with arthritis across the U.S. live their best life.

  • Volunteer

    Volunteer

    Join us and become a Champion of Yes. There are many volunteer opportunities available.

  • Live Yes! INSIGHTS

    Live Yes! INSIGHTS

    Take part to be among those changing lives today and changing the future of arthritis.

  • Partner

    Partner

    Proud Partners of the Arthritis Foundation make an annual commitment to directly support the Foundation’s mission.

Donate


Ways to Give

Every gift to the Arthritis Foundation will help people with arthritis across the U.S. live their best life. Whether it is supporting cutting-edge research, 24/7 access to one-on-one support, resources and tools for daily living, and more, your gift will be life-changing.

Make a Donation

Help millions of people live with less pain and fund groundbreaking research to discover a cure for this devastating disease. Please, make your urgently-needed donation to the Arthritis Foundation now!

Become a Member

Become an Arthritis Foundation member today for just $20 and you'll receive access to helpful tools..... and more.

Make a Honor or Memorial Gift

Honor a loved one with a meaningful donation to the Arthritis Foundation. We'll send a handwritten card to the honoree or their family notifying them of your thoughtful gift.

Gift Planning

I want information on ways to remember the AF in my will, trust or other financial planning vehicles.

Other Ways to Give

  • Match Gift
  • Donate a Car
  • Donor-Advised Funds

Volunteer


Volunteer Opportunities

The Arthritis Foundation is focused on finding a cure and championing the fight against arthritis with life-changing information, advocacy, science and community. We can only achieve these goals with your help. Strong, outspoken and engaged volunteers will help us conquer arthritis. By getting involved, you become a leader in our organization and help make a difference in the lives of millions. Join us and become a Champion of Yes.

Become a Volunteer

More About Volunteering

  • Walk to Cure
  • Jingle Bell Run
  • Do it Yourself Fundraising
  • JA Camp
  • Start a Live Yes! Connect Group
  • Be an Online Community Moderator
  • Local Leadership Board

Live Yes! INSIGHTS


Give Just 10 Minutes.

Tell us what matters most to you. Change the future of arthritis.

By taking part in the Live Yes! INSIGHTS assessment, you’ll be among those changing lives today and changing the future of arthritis, for yourself and for 54 million others. And all it takes is just 10 minutes.

Your shared experiences will help:

- Lead to more effective treatments and outcomes
- Develop programs to meet the needs of you and your community
- Shape a powerful agenda that fights for you

Now is the time to make your voice count, for yourself and the entire arthritis community.

Currently this program is for the adult arthritis community.  Since the needs of the juvenile arthritis (JA) community are unique, we are currently working with experts to develop a customized experience for JA families.

How are you changing the future?

By sharing your experience, you’re showing decision-makers the realities of living with arthritis, paving the way for change. You’re helping break down barriers to care, inform research and create resources that make a difference in people’s lives, including your own.

Get Started

Partner


Meet Our Partners

As a partner, you will help the Arthritis Foundation provide life-changing resources, science, advocacy and community connections for people with arthritis, the nations leading cause of disability. Join us today and help lead the way as a Champion of Yes.

Trailblazer

Our Trailblazers are committed partners ready to lead the way, take action and fight for everyday victories. They contribute $2,000,000 to $2,749,000

Visionary

Our Visionary partners help us plan for a future that includes a cure for arthritis. These inspired and inventive champions have contributed $1,500,00 to $1,999,999.

Pioneer

Our Pioneers are always ready to explore and find new weapons in the fight against arthritis. They contribute $1,000,000 to $1,499,999.

Pacesetter

Our Pacesetters ensure that we can chart the course for a cure for those who live with arthritis. They contribute $500,000 to $999,000.

Signature

Our Signature partners make their mark by helping us identify new and meaningful resources for people with arthritis. They contribute $250,000 to $499,999.

Supporting

Our Supporting partners are active champions who provide encouragement and assistance to the arthritis community. They contribute $100,000 to $249,999.

More About Partnerships

  • Partner with Us
  • Ease Of Use Commendation
  • Let's Get a Grip On Arthritis
  • Promotions that Give Back